Procalcitonin in patients with acute coronary syndrome: correlation with high-sensitive C-reactive protein, prognosis and severity of coronary artery disease.
OBJECTIVE
The aim of this study is to determine the relation of high-sensitive serum C-reactive protein (hsCRP) and procalcitonin with presence and severity of coronary artery disease and early prognosis in patients with acute coronary syndrome (ACS).


RESULTS
Procalcitonin and hsCRP levels were measured at admission and after 48 hours in 50 patients (41 men, 9 women) with ACS. The patients were assigned to three groups according to their clinical diagnosis: unstable angina pectoris (UAP) (Braunwald III-B), non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). Incidences of adverse cardiac events were recorded in a 3-month follow-up. Coronary angiography was performed to evaluate presence and severity of coronary artery disease. In the groups of STEMI, NSTEMI and UAP, procalcitonin (P = 0.01 3, P = 0.045 and P = 0.000 1, respectively) and hsCRP (P = 0.000 1, P = 0.01 and P = 0.00 1, respectively) levels were significantly increased. No significant correlation was found between these markers and the presence and severity of coronary artery disease. There was no correlation between procalcitonin and hsCRP levels at admission and after 48 hours and primary end points after 3 months except in the group of UAP with revascularization procedure. In the group of UAP, hsCRP levels at 48 hours were found higher in the patients with a revascularization procedure (P = 0.04).


CONCLUSIONS
In conclusion, levels of hsCRP and procalcitonin are increased in patients with ACS but failed to correlate with severity of coronary disease and early prognosis.
Sentürk
Tunay
T
Department of Cardiology, Uludag University School of Medicine Bursa, Turkey. tunaysenturk@hotmail.com
Cordan
Jale
J
Baran
Ibrahim
I
Ozdemir
Bülent
B
Güllülü
Sümeyye
S
Aydinlar
Ali
A
Göral
Güher
G
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000789:Angina, Unstable / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D002097:C-Reactive Protein / Q000378:metabolism*; D002116:Calcitonin / Q000097:blood*; D015740:Calcitonin Gene-Related Peptide; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy; D052279:Creatine Kinase, MB Form / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D011379:Prognosis; D011498:Protein Precursors / Q000097:blood*; D012107:Research Design; D012720:Severity of Illness Index; D013577:Syndrome; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood; D014421:Turkey / Q000453:epidemiology
C000606589:CALCA protein, human; D018836:Inflammation Mediators; D011498:Protein Precursors; D019210:Troponin I; D002116:Calcitonin; D002097:C-Reactive Protein; D052279:Creatine Kinase, MB Form; D015740:Calcitonin Gene-Related Peptide